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Abstract
Background:  Feline mammary carcinoma has been proposed as a natural model of highly
aggressive, hormone-independent human breast cancer. To further explore the utility of the model
by adding new similarities between the two diseases, we have analyzed the oncogene HER-2 status
at both the protein and the gene levels.
Methods: Formalin-fixed, paraffin-embedded tissue samples from 30 invasive carcinomas, 7 benign
lesions and two normal mammary glands were analyzed. Tumour features with prognostic value
were recorded. The expression of protein HER-2 was analyzed by immunohistochemistry and the
number of gene copies by means of DNA chromogenic in situ hybridization.
Results:  Immunohistochemical HER-2 protein overexpression was found in 40% of feline
mammary carcinomas, a percentage higher to that observed in human breast carcinoma. As in
women, feline tumours with HER-2 protein overexpression had pathological features of high
malignancy. However, amplification of HER-2 was detected in 16% of carcinomas with protein
overexpression, a percentage much lower than that observed in their human counterpart.
Conclusion: Feline mammary carcinoma would be a suitable natural model of that subset of
human breast carcinomas with HER-2 protein overexpression without gene amplification.
Background
Human epidermal growth factor receptor type 2 (HER-2),
alias c-erbB-2 and neu, is a protooncogene that encodes a
transmembrane glycoprotein similar to the human epi-
dermal growth factor receptor known as the HER-2 pro-
tein. HER-2 has been described in different tumors and
animals. In rats and mice, transforming activity of the neu
oncogene is associated with somatic mutations [1]. In
humans, the abnormal (high) expression of HER-2 pro-
tein (so-called overexpression) correlates with more
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aggressive clinicopathologic features, drug resistance or
sensitivity to specific chemotherapy and specific hormo-
nal therapy regimens in breast cancer [2]. HER-2 protein
overexpression is found in 15–30% of human breast car-
cinomas and comparative fluorescent in situ hybridization
studies have shown that gene amplification is present in
some 85–90% of the cases [2,3]. Chromogenic in situ
hybridization (CISH) has been shown to have good corre-
lation with FISH [4,5], which is currently regarded as a
gold standard method for detecting HER-2 amplification,
but it is not very practical for routine histopathological
laboratories.
Feline and canine mammary tumours have epidemiolog-
ical, clinical, morphologic and prognostic features similar
to those of human breast carcinoma, for which they are
suitable natural models [6,7]. However, similarities con-
cerning both histological picture and biological behavior
are higher in feline cases because, contrary to the situation
in dogs, histological evidence of malignancy is present in
more than 80% of the cases and associates with an aggres-
sive clinical course [8]. Alterations of the HER-2 proto-
oncogene have been described in mammary tumors of
cats [9-11] and dogs [12-16] mostly at the protein level.
The aim of the present work was to investigate the altera-
tions of proto-oncogen HER-2 in normal and tumorous
feline mammary glands at both the protein and gene lev-
els to further explore the value of feline mammary carci-
nomas as natural models of human breast carcinomas.
Methods
Formalin-fixed paraffin-embedded tissue samples from
30 invasive simple epithelial carcinomas, 7 benign lesions
(5 fibroepithelial hyperplasia and 2 simple adenoma)
[17] and two normal mammary glands were analyzed.
Data regarding tumor size and histologic grade of malig-
nancy [18] were recorded. The immunohistochemical
expression of estrogen receptor α (ERα) and progesterone
receptor (PR) was analysed as described previously
[19,20].
Protein HER-2 expression
A commercial polyclonal antibody anti-HER-2/neu pro-
tein (Dakocymation, Glostrup, Denmark) diluted 1:1000
and the avidin-biotin-peroxidase immunohistochemical
method (ABC, Vector, Burlingame, CA) were applied to
deparaffined and dehydrated tissue sections after high
temperature antigen retrieval as described elsewhere [14].
Samples of human breast carcinoma that had been scored
as positive (+++) or negative (-/+) with the HercepTest™
(Dakocymation, Glostrup, Denmark) were used as posi-
tive and negative controls, respectively (Figure 1A). The
results were scored according to the criteria specified in
the HercepTest™ as follows: 0 = no staining or weak and
incomplete membrane staining in less than 10% of the
neoplastic cells; (+) = incomplete and faint membrane
staining in more than 10% of the neoplastic cells; (++)
moderate and complete membrane staining in more than
10% of the neoplastic cells; (+++) = strong and complete
membrane staining in more than 10% of the neoplastic
cells. According to the criteria described above, HER-2
protein overexpression is determined in cases scored as
(++) and (+++).
HER-2 oncogene status
A commercial digoxigenin (DIG)-labeled HER2 DNA
probe generated by Subtraction Probe Technology (SPT™)
was used following manufacturer's recommendations
(Zymed Lab. Inc.). Gene copies visualized by CISH were
distinguished with × 40 and/or × 100 objectives as brown
dots in hematoxylin-stained tissue sections. Positive con-
trols for the standardization of the technique included
formalin-fixed paraffin-embedded tissue samples from
human breast carcinomas which had been scored Her-
cepTest™ (Dako) (+++) positive and had shown HER-2
oncogene amplification by CISH (more than 5 gene cop-
ies/nucleus or large cluster of amplification/nucleus in
more than 50% of cancer cells) (Figure 1B) [4]. Equally
processed tissue samples from non-altered feline mam-
mary gland were run as negative controls in every assay.
Gene detection on feline tissue samples was indicated by
the presence of one to four copies in more than 80% of
the nuclei.
Statistical study
The association between HER-2 protein overexpression
and tumour size as well as histological grade of malig-
nancy and steroid hormones receptors content was
assessed by the Chi-square test. P values < 0.05 were con-
sidered to reflect statistical significance.
Results
Protein HER-2 expression
The HER-2 polyclonal antibody raised against the human
antigen crossreacted with feline tissues as a low percentage
of epithelial cells of non-altered ducts and acini from nor-
mal mammary glands showed a faint, barely perceptible
staining in part of the cell membrane. A similar staining
pattern (+ scoring) was also observed in 2 benign lesions
classified as fibroepithelial hyperplasia (Figure 2A). Pro-
tein overexpression (++ and +++ scorings) was detected in
12 out of 30 carcinomas (40%) (Figure 2B). Carcinomas
with HER-2 overexpression measured more than 2 cm in
their largest diameter, had the highest histologic grade of
malignancy (grade III) (p = 0.011) and lacked estrogen
and progesterone receptors (p = 0.046).
HER-2 oncogene status
One to four brown dots per nucleus were visualized under
bright-field microscope in hematoxylin-counterstainedBMC Cancer 2007, 7:179 http://www.biomedcentral.com/1471-2407/7/179
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sections in more than 80% of the nuclei in tissue samples
from normal mammary gland, benign proliferative
lesions, all 18 carcinomas without protein overexpression
as well as 10 carcinomas with HER-2 protein overexpres-
sion. The remaining 2 carcinomas with HER-2 protein
overexpression had more than five and less than ten dots
per nucleus (Figure 3). Accordingly, 16.6% of carcinomas
with HER-2 protein overexpression had gene amplifica-
tion.
Discussion
Feline mammary carcinomas are, like human breast can-
cers, spontaneous, locally infiltrative and metastasizing
tumors. Therefore, this tumor disease in the cat can serve
as pathogenic and experimental-therapeutic model for the
human counterpart [6]. The present study adds new simi-
larities to widen the utility of the model as it shows that
feline mammary carcinomas overexpress HER-2 protein
as human breast cancers do [2]. In addition, feline carci-
nomas with HER-2 overexpression had features indicative
of high malignancy including large size, high histological
grade and absence of steroid hormone receptors [8]. How-
ever, contrary to the situation in humans, where 85% to
90% of breast carcinomas with HER-2 protein overexpres-
sion have a higher number of copies of the oncogene
HER-2, a low percentage of feline carcinomas with HER-2
protein overexpression (16.6%) presented a number of
HER-2 copies in the limits of what can be considered gene
amplification.
Recent immunohistochemical studies have shown highly
variable figures of HER-2 protein expression in feline
mammary carcinomas ranging from 36% to 90% of the
cases [9-11]. In contrast, more homogeneous results have
been obtained by diverse immunohistochemical methods
both in human and canine mammary cancers. Thus, 15 to
30% of cases of human breast carcinoma present very
high levels (overexpression) of HER-2 protein in the
membrane of tumour cells [2]. In the dog, 18% to 35% of
mammary carcinomas have been shown to overexpress
HER-2 protein [13-16]. Differences in the interpretation
of immunohistochemical data could be responsible for
the highly heterogeneous figures of HER-2 protein expres-
sion in feline mammary carcinomas. Thus, immunostain-
ing was often homogeneously distributed throughout the
cytoplasm of tumour cells but was easily distinguisable of
HER-2 protein expression and oncogene copies in human breast carcinoma Figure 1
HER-2 protein expression and oncogene copies in human breast carcinoma. A) Infiltrating duct carcinoma with HER-2 protein 
overexpression scored (+++). HercepTest, scale bar = 5 µm. B) The same tumour shows more than 5 gene copies/nucleus in 
more than 50% of cancer cells indicating oncogene amplification. CISH, scale bar = 5 µm.
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the stronger membrane staining (Figure 2B). According to
the stringent criteria of the HercepTest, only membrane
staining should be considered specific. However, method-
ology-related problems cannot be excluded. All studies so
far reproted are retrospective using archival formalin-
fixed, paraffin-embedded tissues [9-11], and differences
in antigen preservation may exist. In addition, the rela-
tively low number of cases analysed in each series, ranging
from 30 [10] to 47 [9], should also be taken into account.
Alterations of the HER-2 oncogene in human breast carci-
noma correlate with poor prognosis [3,21]. This has been
also the case in the 2 studies that have analyzed this issue
in dogs with mammary carcinoma [14,15]. In cats, Mil-
lanta and coworkers found correlation between HER-2
protein overexpression in 56% of mammary carcinomas
and shorter survival times but not with histological grade
of malignancy [9]. The number of studies addressing this
issue is too low to draw significant conclusions.
Diverse molecular methods have shown that, in a large
majority of human breast carcinomas, HER-2 protein
overexpression occurs as a consequence of an alteration in
proto-oncogene expression (amplification) that trans-
forms the gene into an oncogene [2,3]. A significant cor-
relation between protein expression and HER-2 mRNA
levels has been found in feline [11] as well as in canine
[12] mammary carcinomas. However, the number of
HER-2 copies was normal in both canine [14] and feline
[11] cases using chromogenic in situ hybrydization and
quantitative PCR, respectively. In this study, 2 mammary
carcinomas with HER-2 overexpression had between 5
and 10 copies/nucleus in some 50% of the tumour cells.
Although still higher than normal, this level of HER-2
amplification is considered doubtful in human breast
cancer and requires to be distinguished from chromo-
somal aneuploidy [3]. For this, fluorescence or chromog-
enic in situ hybridization of chromosome 17 centromere
probes is performed. Proto-oncogene HER-2 maps to
chromosomes 17 and 1 in man and dog, respectively, but
its chromosome location is not known in the cat. Accord-
ingly, feline mammary carcinomas with HER-2 protein
overexpression show normal HER-2 copy number and
would be a suitable natural model of the 10–15% of
human breast carcinomas with HER-2 protein overexpres-
sion without gene amplification.
HER-2 protein expression in feline mammary gland Figure 2
HER-2 protein expression in feline mammary gland. A) Fibroepithellial hyperplasia: some duct epithelial cells showed faint to 
moderate staining in part of the membrane. ABC, scale bar = 10 µm. B) Invasive mammary carcinoma: HER-2 protein overex-
pression scored (+++). ABC, scale bar = 20 µm.
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Conclusion
As human breast cancer, a subset of feline mammary can-
cer overexpress HER-2 protein and have signs indicative of
worse prognosis, although future multivariate prognostic
studies should confirm this finding. Contrary to the
human neoplasm, however, HER-2 protein overexpres-
sion is not associated with gene amplification. For this
reason, feline mammary cancer would be a suitable natu-
ral model of that subset of human breast carcinomas with
HER-2 protein overexpression without gene amplifica-
tion.
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